Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
Entity
UAM. Departamento de MedicinaPublisher
Nature Publishing GroupDate
2010-05-01Citation
10.1038/sj.bjc.6605663
British Journal of Cancer 102.10 (2010): 1468 – 1473
ISSN
0007-0920 (print); 1532-1827 (online)DOI
10.1038/sj.bjc.6605663Funded by
This study was supported by Hoffmann-La Roche, Nutley, NJ, USA.Editor's Version
http://dx.doi.org/10.1038/sj.bjc.6605663Subjects
Aged; Bevacizumab; Capecitabine; Colorectal neoplasms; Neoplasm metastasis; MedicinaRights
© 2010 Cancer Research UKAbstract
BACKGROUND: The efficacy and safety of capecitabine and bevacizumab in elderly patients with metastatic colorectal cancer (mCRC)
considered unsuitable for receiving first-line chemotherapy with an irinotecan or oxaliplatin-based combination were assessed in a
phase II, open, multicentre, uncontrolled study.
METHODS: Treatment consisted of capecitabine 1250 mgm 2 (or 950 mgm 2 for patients with a creatinine clearance of
30–50ml min 1) twice daily on days 1–14 and bevacizumab (7.5 mg kg 1) on day 1 every 3 weeks.
RESULTS: A total of 59 patients aged X70 years with mCRC were enrolled. In an intention-to-treat analysis, the overall response rate
was 34%, with 71% of patients achieving disease control. Median progression-free survival and overall survival were 10.8 months and
18 months, respectively. In all, 32 patients (54%) had grade 3/4 adverse events (AEs), the most common being hand–foot syndrome
(19%), diarrhoea (9%) and deep venous thrombosis (7%). Four patients died because of treatment-related AEs. A relationship was
detected between creatinine clearance p50 ml min 1 and the development of non-bevacizumab-related grade 3/4 AEs. The
incidence of bevacizumab-associated AEs (hypertension, thromboembolic events and proteinuria) was consistent with that of
previous reports in elderly patients.
CONCLUSION: Bevacizumab combined with capecitabine represents a valid therapeutic alternative in elderly patients considered to be
unsuitable for receiving polychemotherapy.
Files in this item
Google Scholar:Feliú Batlle, Jaime
-
Safont, María José
-
Salud, Antonieta T.
-
Losa, Ferrán C.
-
García-Girón, Carlos
-
Bosch, Carles J A
-
Escudero, Pilar
-
López Manzanera, Rafael
-
Madroñal, C.
-
Bolaños, Margarita
-
Gil, Mireia
-
Llombart, Antonio C.
-
Castro-Carpeño, J.
-
González Barón, Manuel
This item appears in the following Collection(s)
Related items
Showing items related by title, author, creator and subject.
-
Exploratory findings from a prematurely closed international, multicentre, academic trial: RAVELLO, a phase III study of regorafenib versus placebo as maintenance therapy after first-line treatment in RAS wild-type metastatic colorectal cancer
Cardone, Claudia; Martinelli, Erika; Troiani, Teresa; Sforza, Vicenzo; Avallone, Antonio; Nappi, Anna; Montesarchio, Vincenzo; Andreozzi, Francesca; Biglietto, Maria; Calabrese, Filomena; Bordonaro, Roberto; Cordio, Stefano; Bregni, Giacomo; Febbraro, Antonio; García-Carbonero, Rocio; Feliú Batlle, Jaime; Cervantes, Andrés; Ciardiello, Fortunato
2019-08-16